Enzyme Inhibitors (therapeutic use) < Enzyme inhibitor < Enzyme-Linked Immunosorbent Assay (methods)

Facettes :

List of bibliographic references indexed by Enzyme inhibitor

Number of relevant bibliographic references: 27.
[0-20] [0 - 20][0 - 27][20-26][20-40]

Ident.	Authors (with country if any)	Title
002169 (2009)	Serge Guerreiro [France] ; Aurélie Ponceau [France] ; Damien Toulorge [France] ; Elodie Martin [France] ; Daniel Alvarez-Fischer [France] ; Etienne C. Hirsch [France] ; Patrick P. Michel [France]	Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization
002550 (2008)	Margarete Zanardo Gomes [Brésil] ; Rita Raisman-Vozari [France] ; Elaine A. Del Bel [Brésil]	A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway
002816 (2007)	Alexandre Kreisler [France] ; Patrick Gele [France] ; Jean-Francois Wiart [France] ; Michel Lhermitte [France] ; Alain Destke [France] ; Régis Bordet [France]	Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease : Fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not
002D59 (2005)	Marina Mapelli [Italie] ; Lucia Massimiliano [Italie] ; Claudia Crovace [Italie, États-Unis] ; Markus A. Seeliger [États-Unis] ; Li-Huei Tsai [France] ; Laurent Meijer [France] ; Andrea Musacchio [Italie]	Mechanism of CDK5/p25 binding by CDK inhibitors
003029 (2004)	N. Hamaue [Japon] ; M. Minami [Japon] ; M. Terado [Japon] ; M. Hirafuji [Japon] ; T. Endo [Japon] ; M. Machida [Japon] ; T. Hiroshige [Japon] ; A. Ogata [Japon] ; K. Tashiro [Japon] ; H. Saito [Japon] ; S. H. Parvez [France]	Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus
003132 (2003)	Olivier Rascol [France] ; Pierre Payoux [France] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France, Portugal] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France]	Limitations of current Parkinson's disease therapy
003232 (2003)	J. G. Delcros [France] ; M. Baudy Floc'H [France] ; C. Prigent [France] ; Y. Arlot-Bonnemains [France]	Proteasome inhibitors as therapeutic agents: Current and future strategies
003358 (2002)	P. Volders [Belgique] ; J. Van Hove [Belgique] ; R. J. U. Lories [Belgique] ; Ph. Vandekerckhove [Belgique] ; G. Matthijs [Belgique] ; R. De Vos [Belgique] ; M. T. Vanier [France] ; M. F. Vincent [Belgique] ; R. Westhovens [Belgique] ; F. P. Luyten [Belgique]	Niemann‐Pick disease type B: An unusual clinical presentation with multiple vertebral fractures
003402 (2002)		Parkinson et mouvements anormaux
003416 (2002)	A. Destee [France] ; R. Bordet [France]	Stimulation dopaminergique continue, stimulation dopaminergique pulsatile
003511 (2002)	A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France]	Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease
003519 (2002)	J. S. Schneider [États-Unis] ; M. Giardiniere [États-Unis] ; P. Morain [France]	Effects of the prolyl endopeptidase inhibitor S17092 on cognitive deficits in chronic low dose MPTP-treated monkeys
003535 (2002)	Marion Blin [France] ; Wim E. Crusio [États-Unis] ; Tobias Hevor [France] ; Jean-Francois Cloix [France]	Chronic inhibition of glutamine synthetase is not associated with impairment of learning and memory in mice
003827 (2001)	Stéphanie Barc [France] ; Guylène Page [France] ; Laurence Barrier [France] ; Alain Piriou [France] ; Bernard Fauconneau [France]	Impairment of the neuronal dopamine transporter activity in MPP+-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors
003839 (2001)	S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France]	Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease
003A60 (2000)	C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France]	Continuous dopamine-receptor stimulation in early Parkinson's disease
003A97 (2000)	M. H. Marion [Royaume-Uni]	Traitement médicamenteux des complications motrices à un stade évolué de la maladie de Parkinson
003B06 (2000)	P. Damier [France]	Quelles stratégies thérapeutiques sont à conseiller à la phase initiale de la maladie ? Les autres traitements
003B57 (2000)	A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France]	The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation
003F06 (1999)	R. J. Ferrante [États-Unis] ; P. Hantraye [France] ; E. Brouillet [France] ; M. F. Beal [États-Unis]	Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase
003F14 (1999)		Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Enzyme inhibitor" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Enzyme inhibitor" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Enzyme inhibitor
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024